Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.[X]
James, you sound awfully confident!!!!
"That EU deal is going to happen, it's just when they are going to announce it"
Looks like Advaxis & Aratana are both presenting at Barclays conference next week. Maybe they finally have some good news for us!
Still no 10Q! Hopefully it was delayed because of news that needs to be added. Would love to see another PR in the morning after this ugly day
Depends how you look at it! Amgen deal they are using our platform and bringing nothing of their own to the table. So in return we got upfront money, almost 500 million in milestone payments plus royalties. In the SELLAS deal we are combining our platform with their WT1 which is already show some incredible results but we still walked away with about 350 million in milestones and worldwide royalties
Not getting my hopes up. Just like they anticipated early India approval and anticipated canine approval. When they PR I believe it
Yes let's talk about burning cash. Because a lot of post that are negative against Dan! Nobody seems to mention actually how many different trials we have going right now and how many of those those are either being paid for by someone else, grant money being used or the bill being split. The company has done an unbelievable job at keeping cost down for the amount of trials we have up and running
Fbg your still pushing this whole Astra deal. Sure hope your right one of these weeks
Well at least he's holding onto the shares unlike Aduro's CEO who keeps dumping shares. He also could have taken his bonuses in cash instead of shares correct.
I'm giving Dan an A- for how he has turned this company around from years past. We have some outstanding partnerships, cash, no debt, our phase 3 has started with SPA and they are hiring like crazy. He is building a very solid foundation for the future. I feel that I made the right choice investing in Advaxis and will continue as long as the pps allows me to. I blame the FDA if anyone for that ridiculously lengthy HOLD. Which I believe was done on purpose. Dan even mentioned it at one conference. I believe he said it was that long because of one individual at the FDA. It's funny that not long after our hold JUNO's trial had it's 2nd or 3rd death and that hold lasted a few days only to have a few more patients pass months later and now the trial is no more. I think someone was trying to put an end to Advaxis but oh how things have changed. Good luck stopping them now.
Fog, I would agree. If the IBB is at its high and we just continue to trade sideways. Well when a pullback happens it will drag us down with it. Danny boy get moving
Juno halts trial for good after 5 deaths.
SELLAS phase 2 update. The future looks great for Advaxis!
"HAMILTON, Bermuda and NEW YORK, March 1, 2017 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company developing novel cancer immunotherapies for an extensive list of cancer indications, today reported updated positive Phase II data from its WT1 immunotherapeutic anti-cancer treatment, galinpepimut-S, in multiple myeloma (MM) patients. Consistent with preliminary data, the updated results indicate a meaningful clinical benefit among high-risk MM patients, positioning galinpepimut-S as a potential first-in-class immunotherapeutic cancer treatment. MM patients typically relapse within 12 months after frontline induction therapy, followed by successful autologous stem cell transplantation (ASCT). The results underscore the potential of SELLAS' lead product candidate, galinpepimut-S, to treat a broad range of cancer indications as monotherapy in the setting of minimal residual disease. Galinpepimut-S was licensed from Memorial Sloan Kettering Cancer Center and is a late-stage innovative WT1 targeted immunotherapeutic.
Updated data from the clinical study show an 88% actuarial overall survival (OS) at the 18-month landmark in 18 evaluable patients. All patients had evidence of minimal residual disease (MRD+) after ASCT and 15 had high-risk cytogenetics at diagnosis. Combined, these characteristics typically result in low progression-free survival (PFS) rates that do not exceed 12 months following ASCT, even while on maintenance therapy with immunomodulatory drugs or proteasome inhibitors. Current median PFS is 23.6 months, while median OS has not been reached. SELLAS' results compare favorably with an unmatched cohort of MM patients with high-risk cytogenetics published [1] by the UK Medical Research Council (Myeloma IX trial). The Company's galinpepimut-S therapy demonstrated a 2.5-fold increase in median PFS, as well as a 2.6-fold increase in the PFS rate at 18 months versus the cohort, which included MM patients with high-risk cytogenetics and MRD+ status post-ASCT and on continuous thalidomide maintenance.
SELLAS' Phase II study started in June 2014 and has enrolled a total of 20 patients, who are being monitored long-term. All non-progression events are confirmed and ongoing (median follow-up at 18 months for survivors). "
I believe they are shooting to start two more phase 3 studies this year. So we could have multiple phase 3 trials going on
Hd, I'm looking forward to ASCO this year
Fbg I hope they did make some kind of deal with Astra. I'm just trying to figure out what it could be. Astra is way behind the other BP companies right now. So they might need us more then anyone
Just trying to make sense of it all. I don't think that the U.S. And Europe are the largest markets. Dan made deals in India(which included other territories) with Bicon, in Asia with GBP and the most recent in the Latin American market with our other partner and wasn't there a deal made in Canada for something or was that just manufacturing
If you were BP. Why would you want to make a deal for our cervical cancer drug when Dan has already given away the rights to the largest markets for cervical cancer? Wouldn't you want to only make a deal if you were able to combine it with your own checkpoint inhibitor and have global rights for all markets. Someone please explain am I way off here
Someone had mentioned that the AACR conference had been pulled off the website. So the question now is why? Did a poster they submitted get denied so they decided not to present or whatever they planned on presenting at that conference. the rights are now owned by someone else. Maybe a deal has been made. Maybe just not attending anymore or someone removed it by accident
I don't know but it sure is nice to see the number decreasing. In other reports a lot of other bio's short interest increased. Something is coming!!!!
James I read the first article this morning and forgot about it and then I was watching NBC nightly news with Lester holt(I think that his name) and they mentioned it as well
Has anyone read or watched all the news out today about how cervical cancer cases are much higher then they thought. What is our lead product for???????
Can we get some news already wtf
We are expecting results final results from GOG 0265 so it could be this conference or the one in April
AZN & BMY better make a move fast. Merck taking a bigger lead with the news this morning
Hd, I know they signed the deal with Stanford for neo-antigen and the Zacks article says the trial they will start in 2017 will be for gastric cancer. The trial they are doing with Merck is also gastric cancer. But the way the article reads sounds like they already have IND approved for neo trial and here I thought we were way ahead. Unless Zacks is getting the two confused
Audro's neo-antigen...... am I reading this correctly? Zacks published a report and it states that Audro already has an IND cleared by the FDA for a neo-antigen trial later this year. How could they have the IND already or better yet why don't we have our approved IND yet? Could Zacks be confusing this with the Audro/Merck trial
Mp, check slide 28 of the CP as far as I know gastric has always been listed.
"ADXS-HER2 Monotherapy
Tumors to include: osteosarcoma, breast, gastric, and other cancers"
So tell me what you think! Merck signs deal with Audro for gastric cancer. What do you take away from this? First we can cover gastric under our Her2 trial. Why would Merck go to Audro when they already have a relationship with us. I personally think they wanted another trial like the Prostate trial which Merck really wouldn't have to put much out of pocket and Danny boy said "I don't think so". Merck apparently likes what they are seeing with the Prostate trial to go after another listeria based trial. After Advaxis struck the Amgen deal there won't be any more free trials for anyone.
Interview with Sara Bonstein on Advaxis webpage if anybody wants to give a listen
I don't think any have. Just like the most recent Amgen deal they purchased over 3 million shares but not on the open market but the spike in volume does seem to suggest that some news maybe coming or just new investors moving money into something new
We can all say what we want but the Aratana(PETX) deal might have been the only deal available at the time. We were not that strong of a company as we are today. Maybe BP was waiting for us to go belly up. It does seem that Aratana started running out of money and lucky for them our shares put some extra change in their pockets and then BP came to save them. AT-014 was last on the list of things to get done but to this day I still think Dan made the right move selling that off so the company could focus on the human pipeline. He got us a very nice deal with Amgen. One that nobody here saw coming. 2017 will be big or bust.
I didn't find the answer very helpful either but even if AT-014 gets approval in Q1 of 2017. I bet it does nothing for our pps. Advaxis has a lot on it's plate for 2017 and at this point Aratana and AT-014 is last on my list. I feel bad for all the dogs that could be benefiting from this product but it should have never taken this long to approve and bring to market.
I'll take a business update! I'll take as much info as they are willing to give but I do believe it is 2017 or BUST for Advaxis
Hey James why do you feel we will be receiving a business update soon. Was this already scheduled, just your opinion or did Dan mention it when you spoke to him, thanks
So added today but just a bit to early at 7.53. I love reading all these post that we are flushed with cash and there was no need for the additional 30 million after Amgen deal. Why don't you guys figure out how much it cost to run a business with 80 employees now plus all the other overhead that I won't mention and then tell me we didn't need the money. Don't be surprised if we need more money 1st half of 2017 but I hope that comes from a milestone payment.
See you all in the new year. Looking to add today before 2017 and that's it. It's 2017 or bust tired of waiting
Not a fan of this news at all. I think Greg had a big part in all the BP deals and wasn't he just given a new role and added to the BOD. Did they know he was leaving and wanted him added to the BOD before his departure took place.
So according to obi10 "phase 3 study is dead in the water"